Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 907828 drug-drug interaction study in solid tumors
NCT05372367Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of brigimadlin in solid tumor (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of BI 907828 in plasma over the time interval from 0 to 24 hours, Maximum measured concentrations of BI 907828 in plasma at 15 days and 1 more. Started Aug 2022; status: completed.
02
Drugs
brigimadlin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05372367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372367.